ODD | Neurophth Therapeutics’ Treatment of Leber’s Hereditary Optic Neuropathy (LHON) Gene Therapy (NR082) Was Granted Orphan Drug Designation by U.S. FDA, Ophthalmic Gene Therapy Ushered in an Outbreak Period

Neurophth Announces Presentations at ASGCT and ARVO Annual Meetings

China's First Gene therapy Company Neurophth Finished $18M series A Financing

Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer

NEUROPHTH CLOSES RMB 400 MILLION SERIES B FINANCING